Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation
The present study comprehensively elucidates the molecular features of EGFR p.L861Q mutation and underscores the optimal therapeutic choice of first-line EGFR-TKI based on brain metastatic status.
Authors
- Lanlan Pang (ORCID: https://orcid.org/0000-0002-4932-8117)
- Weitao Zhuang (ORCID: https://orcid.org/0000-0002-8679-4109)
- Jun Liao (ORCID: https://orcid.org/0000-0002-2017-5065)
- Meng-di Li
- Junjun Li (ORCID: https://orcid.org/0000-0002-4080-5458)
- Bin Li (ORCID: https://orcid.org/0000-0002-7774-5452)
- Li Zhang (ORCID: https://orcid.org/0000-0003-0595-0761)
- Wenfeng Fang
- Yihua Huang (ORCID: https://orcid.org/0000-0001-6736-7913)
Institutions
- Sun Yat-sen University (CN)
- Burning Rock Biotech (China) (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Neoplasia
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1016/j.neo.2024.101073
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.84
Funders
- National Natural Science Foundation of China
- Sun Yat-sen University
- Sun Yat-sen University Cancer Center